Refractory rash at PICC puncture site during pegylated liposomal doxorubicin chemotherapy
'Limited evidence exists regarding skin toxicity management, particularly when these reactions occur near vascular access sites. The clinical complexity is compounded by both the absence of standardized guidelines and the prolonged use of occlusive transparent dressings, which may worsen skin integrity, increase infection risks, and potentially necessitate premature catheter removal—leading to unplanned treatment delays" Shuping et al (2026).